PALM BEACH, Florida, June 19, 2018 /PRNewswire/ --
MarketNewsUpdates.com News Commentary
Thehealthcare solutions sector of the overarching biotech industry is an active market as of late, with leaders in the space unveiling new breakthroughs, therapies and products designed to meet a variety of healthcare patient needs and conditions. For example,
In 2017 the first next generation troponin assay for the early diagnosis of heart attack was approved for use in the U.S. by the FDA. High sensitivity ("HS") troponin assays have been in use in other parts of the world for over 7 years. These assays are performed on state of the art central laboratory analyzers, which are expensive and typically take about an hour to turnaround results, when minutes are vital. The key to the MIDS technology is its ground breaking ability to magnetically detect and measure diagnostic assay beads in low enough numbers to support a HS troponin assay. MML aims to embody this highly compact technology into an easy to use, hand-held MIDS Cardiac device for rapid diagnosis in emergency rooms, or by paramedics responding to chest pain patients at the scene.
2018 Quantitative Testing Results - Quantitative testing was conducted to (a) determine the minimum number of assay beads that can be detected; and (b) to prove linearity of detection signal to quantified bead numbers. MML has been advised by Future Diagnostics Solutions B.V. (a leading assay developer engaged to MML) that a capability to detect below 200,000 assay beads and preferably less than 110,000 is required to support a HS troponin test. Two brands of beads were tested: GE Sera-Mag™ (3?m) and Thermo Fisher Scientific M-270 Dynabeads® (2.8 ?m), both of which are regarded as suitable for a HS troponin assay and have similar paramagnetic characteristics. The MIDS LoD of both these brands was seen on a reliable, repeatable basis at around 50,000 beads, with good signal linearity (required for accurate assay quantitation) at higher numbers. This number of beads detected at the LoD is approximately four times lower than the maximum threshold and therefore well within the range advised by Future Diagnostics as suitable for a HS troponin assay. MML Managing Director and Chief Scientific Officer Dr. Nasser Djennati commented: "MIDS is a hugely challenging development. The results of this second round of testing are quite extraordinary, as magnetic detection at this level for this application is unheard of. We can now move forward and apply the MIDS detection to established assay techniques used in conventional analyzers as we seek to deliver state-of-the-art laboratory standard, high sensitivity cardiac troponin testing at the Point of Care." Read this and more news for Zenosense at http://www.marketnewsupdates.com/news/zeno.html
Other recent and current developments in the healthcare industry include: BioTelemetry Inc. (NASDAQ: BEAT) recently announced the release of its next-generation wireless blood glucose monitor for diabetes management. As an industry pioneer, BioTel Care developed the first FDA-cleared, cellular-enabled glucometer which supports real-time transmission and consolidation of patient data in an FDA-cleared cloud. Building on the success of this technology, BioTel Care is launching its next-generation blood glucose monitor, which includes an innovative touch-screen user interface, enabling patients to easily test blood glucose levels while capturing additional personal health data. The monitor's remote capabilities allow patients to quickly communicate a wide range of relevant health information to their care providers. Clinicians can access and track their patients' data through the BioTel Care cloud and can provide immediate feedback, as needed, directly to their patients via the new monitor's messaging feature.
Fortress Biotech's (NASDAQ: FBIO) and Caelum Biosciences, Inc. ("Caelum") recently announced that Columbia University ("Columbia") will present a complete analysis of cardiac data from the Phase 1b trial of CAEL-101 (mAb 11-1F4) for the treatment of relapsed or refractory amyloid light chain ("AL") amyloidosis in a poster session at the American Society of Echocardiography (ASE) 29th Annual Scientific Sessions, to be held June 22-26, 2018, in Nashville, Tenn. Investigators concluded that the Phase 1b trial of CAEL-101 in AL amyloidosis is the first trial to show a significant improvement in global longitudinal strain ("GLS") after exposure to an anti-fibril specific mAb in subjects with AL amyloidosis experiencing cardiac involvement. GLS is a sensitive measure of cardiac functional impairment in patients with cardiac involvement, and may detect early cardiac functional improvement and be an important predictor of cardiac survival.
Irhythm Technologies Inc. (NASDAQ: IRTC) closed Monday up slightly closing at $84.41 by the final bell. iRhythm Technologies is a leading digital health care solutions company focused on the advancement of cardiac care that in mid May had announced results of a study which utilized Zio by iRhythm, an extended continuous cardiac monitoring system, to provide a comprehensive picture of the burden of atrial fibrillation (AF) in patients. Utilizing this data in combination with electronic health record data, the researchers concluded that an increase in the burden of atrial fibrillation (AF) is independently associated with a higher risk of ischemic stroke and arterial thromboembolism in patients who are not taking anticoagulant medication.
Johnson & Johnson (NYSE: JNJ) recently announced the U.S. Food and Drug Administration (FDA) approval of the iDESIGN Refractive Studio, making it the only system to use topography-integrated, wavefront-guided technology.2 This allows doctors to take a precise measurement of the eye inside and out to deliver a LASIK procedure personalized to the individual patient. It is approved for myopia, hyperopia, and mixed astigmatism. Additionally, it is the only available LASIK platform indicated for monovision LASIK in presbyopic myopic patients. Monovision is a procedure designed for patients over 40 years old who are experiencing blurry near vision due to aging of their eyes. In the U.S., an estimated 130 million people3 could potentially benefit from a monovision procedure, which includes improved distance and near vision.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated forty four hundred dollars for news coverage of the current press releases issued by Zenosense, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Media Contact: firstname.lastname@example.org +1(561)325-8757
Subscribe to our Free Newsletters!
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...
Acanthosis nigricans is a skin condition in which discoloration and hyperpigmentation of the skin ...
Gastrointestinal Bleeding refers to hemorrhage that occurs from one or more portions of the ...View All